Experimental cholesterol pill cuts heart attack risk with 'convenient' once-daily dose

A new daily pill could provide an easier more convenient way to lower cholesterol and reduce heart attack and stroke liability The experimental medication called Obicetrapib underwent a Phase clinical trial at Monash University in Australia The trial included more than people averaging years of age All had either been diagnosed with heart syndrome or had genetically high cholesterol according to a university press release THIS CHEAP PANTRY STAPLE COULD BE KEY TO LOWERING CHOLESTEROL NEW RESEARCH SUGGESTSAll participants were receiving maximum tolerated doses of cholesterol-lowering therapy One group received Obicetrapib and another group took a placebo while still maintaining their existing cholesterol drugs After weeks the participants taking the new drug revealed a reduction in LDL cholesterol and a drop in lipoprotein a Lp a the release stated The findings were presented last month at the European Atherosclerosis Society Congress in the U K and were also published in The New England Journal of Medicine WOMEN S HEART MALADY EXPOSURE COULD BE PREDICTED UP TO YEARS IN ADVANCE WITH ONE BLOOD TEST ASSESSMENT FINDS We know that several people at high pitfall of heart attack or stroke don t get their cholesterol levels low enough even on the best available treatments commented analysis lead Professor Stephen Nicholls director of Monash University s Victorian Heart Institute and Monash Physical condition s Victorian Heart Hospital in the release Obicetrapib offers a promising new option not only did it lower LDL cholesterol by over but we also saw a reduction in Lp a which is much harder to treat and has been linked to increased heart ailment pitfall Low-density lipoprotein LDL which is sometimes called bad cholesterol is associated with negative physical condition effects when present in high amounts LDL can build up in the blood vessels and increase heart attack and stroke vulnerability the researchers cautioned Lipoprotein a or Lp a is a protein that is known to greatly increase the chances of a heart attack when it s present in high levels in the blood Unlike LDL Lp a is an inherited peril factor that can t be modified with healthy behaviors or medications Obicetrapib was discovered to be well-tolerated by the participants the researchers noted This could be a valuable tool in the fight against heart affection Nicholls added It s convenient it s effective and it may help close the gap for patients who ve run out of options CLICK HERE TO SIGN UP FOR OUR PHYSICAL CONDITION NEWSLETTERThe assessment which was funded by NewAmsterdam Pharma a developer of Obicetrapib that is based in the Netherlands did have certain limitations the researchers noted For example the participants were not chosen based on high Lp a which means the survey did not determine how the drug impacted those with elevated levels of the protein Additionally the evaluation assessed changes in LDL levels but did not measure actual heart attack or stroke outcomes For more Healthcare articles visit www foxnews com healthMore studies are needed to follow patients for longer time periods and to include more diverse cohorts the researchers acknowledged Fox News Digital reached out to the researchers for additional comment